Research Topics
Genomes and Genes | R HassanSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1PJingli Zhang
Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264, USA
Anticancer Res 32:5151-8. 2012..To determine if early passage tumor cells obtained from patients with mesothelioma continue to express the tumor differentiation antigen mesothelin and their sensitivity to the anti-mesothelin immunotoxin SS1P...
Mesothelin-targeted agents in clinical trials and in preclinical developmentRonan J Kelly
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Mol Cancer Ther 11:517-25. 2012..This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development...- Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardiumRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264, USA
Hematol Oncol Clin North Am 19:1067-87, vi. 2005..Given the rarity of these tumors, it is difficult to obtain precise information regarding their incidence, natural history, and optimal management... - Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancerRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute NIH, 37 Convent Drive, Bethesda, MD 20892, USA
Clin Cancer Res 12:447-53. 2006..To determine whether mesothelin, a cell surface protein highly expressed in mesothelioma and ovarian cancer, is shed into serum and if so to accurately measure it... - Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conferenceR Hassan
National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264 USA
Ann Oncol 17:1615-9. 2006..This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research... - Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenograftsRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 12:4983-8. 2006..The goal of this study was to determine if radiation therapy in combination with the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) would result in enhanced antitumor activity against mesothelin-expressing xenografts in nude mice... - Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapyRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
Lung Cancer 68:455-9. 2010..MORAb-009 is a chimeric anti-mesothelin monoclonal antibody... - Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892 4264, USA
Clin Cancer Res 13:5144-9. 2007..To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers... - Mesothelin targeted cancer immunotherapyRaffit Hassan
Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 4264, USA
Eur J Cancer 44:46-53. 2008..These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy... - Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancersRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
Clin Cancer Res 16:6132-8. 2010..5 to 400 mg/m(2). Disease evaluation with computed tomography occurred on day 35. Subjects with responding or stable disease could receive additional cycles of MORAb-009... - Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenograftsRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, and the Clinical Center, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 13:7166-71. 2007..To determine the antitumor activity of the anti-mesothelin immunotoxin SS1P in combination with gemcitabine against mesothelin-expressing tumor xenografts... - Mesothelin: a new target for immunotherapyRaffit Hassan
Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 10:3937-42. 2004..There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas... - Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literatureR Hassan
Department of Medicine Hematology Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, USA
Leuk Lymphoma 45:2149-52. 2004..2 years) after the diagnosis and treatment of HCL. Further studies are needed to clarify whether leukemias seen in patients following the treatment of their HCL are incidental findings or related to HCL and its treatments... - Localization of mesothelin in epithelial ovarian cancerRaffit Hassan
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
Appl Immunohistochem Mol Morphol 13:243-7. 2005..Patients whose tumors express mesothelin could be eligible for participation in clinical trials of novel agents targeting mesothelin... - Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1Raffit Hassan
Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 10:16-8. 2004..The development of human antibodies against LMB-1 was detected using a serum neutralization and ELISA... - A binding domain on mesothelin for CA125/MUC16Osamu Kaneko
Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
J Biol Chem 284:3739-49. 2009..The identified CA125-binding domain significantly inhibits cancer cell adhesion and merits evaluation as a new therapeutic agent for preventing or treating peritoneal malignant tumors... - Humoral immune response to mesothelin in mesothelioma and ovarian cancer patientsMitchell Ho
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 11:3814-20. 2005..Here we addressed the issue of whether mesothelin elicits a humoral immune response in patients with mesothelioma and ovarian cancer... - Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumorsYujian Zhang
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Proc Natl Acad Sci U S A 104:17099-104. 2007.... - Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patientsMasanori Onda
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
J Immunol 177:8822-34. 2006..Our results indicate that a relatively small number of discrete immunogenic sites are associated with PE38, most of which can be eliminated by point mutations... - Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing miceYujian Zhang
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-4264, USA
Clin Cancer Res 12:4695-701. 2006..This effect is not secondary to increased tumor uptake of the immunotoxin. Synergy could be due to improved immunotoxin distribution within the tumor or could involve factors released by other cell types in the tumors... - Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomasQian Li
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Anticancer Res 24:1327-35. 2004..Clinical studies of SS1(dsFv)PE38 in patients with peritoneal mesotheliomas are ongoing... - Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesotheliomaMasanori Onda
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
Clin Cancer Res 12:4225-31. 2006..To establish monoclonal antibodies (mAb) against megakaryocyte potentiation factor (MPF) and detect MPF in the blood of patients with mesothelioma... - Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion proteinNoriko Sato
Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
J Nucl Med 46:1201-9. 2005..The specific activity of DOTA-biotin had a significant effect on its tumor uptake. Therapeutic tumor doses were obtained without dose-limiting toxicity... - Immunotoxin treatment of cancerIra Pastan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Annu Rev Med 58:221-37. 2007..Strategies to overcome these limitations are being pursued... - Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1PRobert J Kreitman
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
Clin Cancer Res 15:5274-9. 2009..To conduct a phase I trial of recombinant immunotoxin SS1P given by continuous infusion in chemoresistant solid tumors expressing mesothelin... - Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in miceDavid Filpula
Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New Jersey 08854, and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Bioconjug Chem 18:773-84. 2007..Since the bioconjugates can also exhibit the attributes of passive targeting via enhanced permeability and retention, this is the first demonstration of a pivotal role of active targeting for immunotoxin bioconjugate efficacy... - Immunotoxin therapy of cancerIra Pastan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institues of Health, 37 Convent Drive, Bethesda, MD 20892 4264, USA
Nat Rev Cancer 6:559-65. 2006..Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy... - A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptakeYujian Zhang
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
Cancer Res 70:1082-9. 2010..Further, we suggest one basis to understand why chemotherapy and antibody-based therapies cooperate when combined in cancer treatment... - New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISAMasanori Onda
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
Clin Cancer Res 11:5840-6. 2005.... - Identification of novel human CTL epitopes and their agonist epitopes of mesothelinJunko Yokokawa
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 11:6342-51. 2005..CONCLUSIONS: The identification of novel CTL agonist epitopes supports and extends observations that mesothelin is a potential target for immunotherapy of pancreatic and ovarian cancers, as well as mesotheliomas... - Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinomaS Guruswamy
Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
J Natl Cancer Inst 93:516-25. 2001..93; P =.02). CONCLUSIONS: At clinically achievable concentrations, all retinoids tested decrease the growth fraction, induce differentiation and apoptosis. Induction of MUC1 expression is implicated in the mechanisms of action... 
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxinRobert Sarnovsky
Laboratory of Molecular Biology, CCR, NCI, NIH, HHS, Bethesda, MD 20892, USA
Cancer Immunol Immunother 59:737-46. 2010....- Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitroRaffit Hassan
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Clin Cancer Res 8:3520-6. 2002..Our results also show low concentrations of an immunotoxin targeting mesothelin is cytotoxic to mesothelin-expressing human tumors by inducing apoptosis... - Mesothelin expression in human lung cancerMitchell Ho
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 13:1571-5. 2007..To investigate mesothelin as a new target for immunotherapy in lung cancer... - Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitisRaffit Hassan
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
Am J Clin Pathol 124:838-45. 2005..Our results demonstrated mesothelin expression in the majority of pancreaticobiliary adenocarcinomas and no expression in normal pancreatic tissues and in chronic pancreatitis... - Malignant mesothelioma of the inguinal canal with an unusually long survivalJanice M Walshe
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA
Am J Clin Oncol 31:306-7. 2008 - Update on malignant mesotheliomaKaren Antman
Provost, Boston University Medical Campus Dean, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Oncology (Williston Park) 19:1301-9; discussion 1309-10, 1313-6. 2005..Recent randomized trials have shown significant improvement in time to progression and survival for the addition of new antifolates to platinum-based chemotherapy... - Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan
Morphotek Inc, 210 Welsh Pool Road, Exton, PA, USA
Cancer Immun 7:20. 2007..We have in fact initiated a Phase I clinical study enrolling patients with mesothelin-positive pancreatic, mesothelioma, non-small cell lung and ovarian cancers... - Mesothelin, a possible target for immunotherapy, is expressed in primary AML cellsDaniel Steinbach
University Children s Hospital Jena, Germany
Eur J Haematol 79:281-6. 2007..SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin which is undergoing clinical evaluation in patients with mesothelin-expressing tumors... - Mesothelin is shed from tumor cellsMitchell Ho
Cancer Epidemiol Biomarkers Prev 15:1751. 2006